Neuronetics (STIM)
(Real Time Quote from BATS)
$1.89 USD
+0.07 (3.85%)
Updated Jul 10, 2024 03:25 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
STIM 1.89 +0.07(3.85%)
Will STIM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for STIM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STIM
Neuronetics (STIM) Expands NeuroStar Portfolio With New Launch
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
STIM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
Neuronetics (STIM) Progresses in MRD and TRD With New Deal
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
Other News for STIM
BlueCross BlueShield MI and Cambia Health Solutions Expand TMS Access for Depressed Adolescents
NeuroStar Showcases Cutting-Edge Research at Clinical TMS Society Annual Meeting
Neuronetics announces participation at CTMSS
Director Robert Cascella Acquires 50,000 Shares of Neuronetics Inc (STIM)
Neuronetics And 3 Other Stocks Under $3 Insiders Are Buying